We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Rheumatology

Journal Scan / Research · August 08, 2022

Anti-TNF Multivalent Compound for Patients With Rheumatoid Arthritis

Arthritis & Rheumatology (Hoboken, N.J.)


Additional Info

Arthritis & Rheumatology (Hoboken, N.J.)
Phase II/III results of the anti-TNF multivalent NANOBODY® compound 'ozoralizumab' in patient with rheumatoid arthritis (OHZORA trial)
Arthritis Rheumatol 2022 Jun 21;[EPub Ahead of Print], T Takeuchi, M Kawanishi, M Nakanishi, H Yamasaki, Y Tanaka

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading